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High-density lipoprotein (HDL) provides a pathway for the passage of lipid peroxides
and lysophospholipids to the liver via hepatic scavenger receptors. Perhaps more
importantly, HDL actually metabolizes lipid hydroperoxides preventing their accumulation
on low-density lipoprotein (LDL), thus impeding its atherogenic structural modification.
A number of candidates have been suggested to be responsible for HDL’s antioxidant
function, with paraoxonase-1 (PON1) perhaps the most prominent. Here we review
the evidence for HDL anti-oxidative function and the potential contributions of
apolipoproteins, lipid transfer proteins, paraoxonases and other enzymes associated
with HDL.
Keywords: apolipoprotein A1, glycated low-density lipoprotein, high-density lipoprotein, oxidized low-density
lipoprotein, paraoxonase 1
Introduction
Whilst atherogenesis is a complex process, macrophage-derived foam cell formation resulting from
the uptake of circulating low-density lipoprotein (LDL) is of fundamental importance. Despite
this, foam cell formation with LDL is impossible to instigate in vitro due to insufficient monocyte-
macrophage LDL receptor expression (Steinberg and Witztum, 2010). It was, however, discovered
that experimental chemical modification of LDL permitted its rapid receptor-mediated uptake
by monocyte-macrophages to form foam cells. This led to the identification of the scavenger
receptors (Stocker and Keaney, 2004; Steinberg and Witztum, 2010) and opened new avenues of
research to identify possible in vivo atherogenic modifications of LDL. Oxidation, glycation, and
homocysteinylation have all been explored. Although, clinical trials of chain-breaking antioxidants
proved disappointing in the prevention of atherosclerotic cardiovascular disease (Heart Protection
Study Collaborative, 2002), other systems which might oppose potentially atherogenic LDL
modifications, including high-density lipoprotein (HDL) merit further attention.
We have contributed to the notion that paraoxonase 1 (PON1), an enzyme located almost
exclusively on HDL, is important in impeding oxidative modification of LDL (Mackness
et al., 1991, 1993; Durrington et al., 2001). Our recent work has focused on glycation as an
atherogenic modification of LDL and this too has led us back to PON1 (Younis et al., 2013).
Other HDL components have also been conjectured to be involved in preventing atherogenic
LDL modification and evidence increasingly points to a coordination of these with PON1.
Understanding these protective mechanisms might reveal important pathways which could be
manipulated therapeutically to prevent atherosclerosis.
Atherogenic LDL Modification
The discovery that chemical modification of LDL by acetylation increases its affinity for
macrophage scavenger receptors and reduces binding to the physiological LDL receptor led to
Soran et al. Antioxidant properties of HDL
a search for naturally occurring modifications which might
have similar effects (Steinberg and Witztum, 2010). The ensuing
hypothesis that lipid peroxidation products produced on LDL
when subjected to attack by oxygen free radicals are responsible
for changes in the apolipoprotein B100 (apoB) of LDLwhich alter
its receptor binding preferences remains compelling despite the
disappointing lack of effect of chain-breaking antioxidants (Heart
Protection Study Collaborative, 2002; Stocker and Keaney, 2004;
Steinberg and Witztum, 2010). Perhaps unsurprisingly given the
safeguards against oxygen free radical damage, oxidized LDL is
only found at low circulating concentrations, although it has
been argued that higher levels might occur at sites where LDL is
sequestered and this might include the arterial wall (Stocker and
Keaney, 2004).
We were surprised to discover that glycated apoB was present
in the circulation at relatively high concentrations of around
2–3 mg/dl in healthy people and at higher levels in diabetes
and in hypercholesterolaemia (Tames et al., 1992). This has
been confirmed by immunoassays detecting epitopes unique to
glycated LDL and we have also shown that atherogenic small
dense LDL is more heavily glycated than other LDL subfractions
in vivo, and is more susceptible to glycation in vitro (Younis et al.,
2009, 2010). Glycated LDL also has a longer circulating half-life
than unmodified LDL, and is removed from the circulation by
route(s) not involving the LDL receptor. Interestingly, statins
also reduce circulating concentrations, likely by reducing LDL
available to undergo glycation (Younis et al., 2010).
Homocysteine may also be atherogenic; thiolation of LDL free
amino groups by homocysteine thiolactone increases its uptake
by macrophages (McCully, 1993). Interestingly the lactonase
activity of PON1 will detoxify homocysteine thiolactone in
addition to its role in preventing LDL oxidation (see later).
HDL Antioxidative Activity
Lipid hydroperoxides formed on LDL will migrate to its surface
as a result of their greater hydrophilicity, facilitating their
transfer to HDL (Parthasarathy et al., 1990). This transfer can
occur directly between lipoprotein phospholipid monolayers,
but may be assisted by lipid transfer proteins (see Figure 1).
HDL might thus provide a pathway for the passage of
lipid peroxides and lysophospholipids to the liver via hepatic
scavenger receptors. Perhaps more importantly, HDL actually
metabolizes lipid hydroperoxides preventing their accumulation,
consequently impeding the atherogenic structural modification
of LDL (Mackness et al., 1991). We have observed that when
HDL is incubated with LDL under oxidizing conditions the
accumulation of lipid peroxides on LDL is decreased, but the
concentration of lipid peroxides on HDL remains similar to that
observed when HDL alone is oxidized (Mackness et al., 1991,
1993). This effect of HDL is obvious within 3 h, by which time
typically more than 50% of the lipid peroxidation of LDL which
would occur in the absence of HDL has been prevented. These
results suggest that this effect is related to enzymatic activity
associated with HDL, and not chain-breaking antioxidants or
transition metal chelation (Mackness et al., 1993; Durrington
et al., 2001). It should also be noted that this anti-oxidative
function of HDL is observed in vitro with similar protein
concentrations of LDL and HDL; greater suppression of LDL
oxidation might be expected when HDL concentrations exceed
those of LDL as they do in the interstitial fluid. In fact, the
accumulation of oxidized lipids in HDL likely results not only
from their transfer from LDL but also from triglyceride-rich
remnant particles and endothelial cells. The antioxidant effects of
HDL are now well established and have been demonstrated in a
number of experimental systems (Kontush and Chapman, 2010).
HDL Antiglycative Activity
We have also shown that HDL can impede the modification of
LDL by glycation in vitro, and that this anti-glycative function
of HDL is more marked with HDL obtained from people
with higher serum PON1 activity (Younis et al., 2013). We
noted in these experiments that LDL is relatively resistant to
glycation in the absence of oxygen, such that supraphysiological
glucose concentrations are required. Oxidation appears to
accompany in vitro glycation and the process is best regarded as
glycoxidation. The lipid peroxidation of LDL that accompanies
in vitro glycation is also impeded in the presence of HDL.
Adduction of lipid peroxidation products to the ε amino groups
of apoB lysine residues in vivo may render these groups more
susceptible to combination with glucose. Thus, in vivo exposure
of LDL to oxygen free radicals may predispose to glycation and
explain the observed high levels of circulating glycated LDL.
The effect of HDL on glycation may thus be related to its
anti-oxidative function. An alternative hypothesis is that the
oxidized analog of glucose, gluconolactone, is more involved in
apoB glycation, and that this step might be affected by PON1’s
lactonase activity.
Paraoxonase 1
PON1 is produced in the liver and circulates on HDL. There is
a significant body of evidence to support a role for PON1 in
atherosclerosis, and in particular against oxidation, not least its
capacity to hydrolyze lipid hydroperoxides.
We demonstrated that the HDL fraction containing PON1
was most active in impeding Cu2+ induced lipid peroxide
accumulation on LDL (Mackness et al., 1993). It has since
been suggested that it is not PON1 which is responsible for
this effect, an argument supported by reports that more highly
purified PON1 isolated from HDL and recombinant water-
soluble variants of PON1 do not hydrolyze lipid peroxides
(Draganov et al., 2005; Kontush and Chapman, 2010). It is
however exceptionally difficult to separate PON1 from other
HDL components, such as apolipoprotein AI (apoAI) and
phospholipase A2 (PLA2), without subjecting it to conditions
which might affect its catalytic activity (Ben-David et al., 2015).
Similarly, the increased polarity of recombinant PON1 would
be expected to compromise its ability to hydrolyze hydrophobic
substrates (Harel et al., 2004; Draganov et al., 2005; Bajaj et al.,
2014). More lipophilic recombinant PON1 might be expected
to have improved functionality, but is more difficult to isolate,
a factor which will prove important in the development of
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FIGURE 1 | The role played by high density lipoprotein (HDL) in the metabolism of lipid hydroperoxides and lysolipids and protection against
atherogenesis. Apo AI, apolipoprotein AI; apoB100, apolipoprotein B100; apoM, apolipoprotein M; CETP, cholesteryl ester transfer protein; glyc apoB, glycated
apolipoprotein B; GSPx, glutathione peroxidase; LDL, low density lipoprotein; LDLR, low density lipoprotein receptor; oxLDL, oxidized low density lipoprotein; PLA2,
phospholipase A2; PLTP, phospholipid transfer protein; PON1, paraoxonase1; RAS, reactive oxygen species; SCARA1, scavenger receptor A1; SCARB1, scavenger
receptor B1.
recombinant PON1 for therapeutic use (Bajaj et al., 2014).
Interestingly, HDL from avian species, which lacks paraoxonase
activity, does not protect human LDL against lipid peroxidation
(Mackness et al., 1998). Similarly, PON1 knockout mice are
more susceptible to atherosclerosis and their HDL is less able to
prevent the accumulation of lipid peroxides on human LDL (Shih
et al., 1998), whereas transgenic rodentmodels expressing human
PON1 are protected against atherosclerosis (Tward et al., 2002;
Zhang et al., 2010).
Epidemiological studies have consistently shown that PON1
activity is independently inversely associated with coronary
events (Mackness et al., 2003; Wang et al., 2012). A recent meta-
analysis, which considered 47 such studies, reported that PON1
activity was 19% lower in patients suffering from coronary heart
disease than in unaffected controls (Wang et al., 2012). Other
prospective studies expanded on the negative correlation between
PON1 activity and coronary heart disease by also reporting
circulating levels of lipid peroxidation products, linking these to
PON1 anti-oxidative activity (Bhattacharyya et al., 2008; Karlsson
et al., 2015).
A number of medical conditions including diabetes mellitus,
chronic kidney disease, familial hypercholesterolaemia and
inflammatory arthritides are associated with both decreased
serum PON1 activity and increased CVD risk (Soran et al.,
2009). PON1 activity is decreased in both type 1 and 2 diabetes
(Mackness et al., 2000, 2002) and lower levels are associated with
microvascular complications (Mackness et al., 2000, 2002; Hofer
et al., 2006).
PON1 has several genetic polymorphisms, the most
extensively researched of which is the R192Q variant. This
polymorphism has a substantial effect on PON1’s capacity to
hydrolyze paraoxon and homozygotes and heterozygotes for
the R allele are more resistant to parathion (paraoxon is formed
from this widely used organophosphate pesticide once it enters
the body) than QQ homozygotes (Mackness et al., 2001; Cherry
et al., 2002; Wheeler et al., 2004). Other activities of PON1, such
as phenyl acetate hydrolysis, which proceed at faster rates, are,
however, unaffected by the R192Q polymorphism. In the case
of the protective effect of HDL against LDL oxidation, HDL
from 192QQ homozygotes is most effective in preventing the
accumulation of lipid peroxides on LDL (Mackness et al., 1997;
Durrington et al., 2001), but this effect is small in comparison
to the huge variation in serum PON1 activity. Nonetheless
192QQ homozygotes have been reported to have reduced
CVD risk (Mackness et al., 2001; Wheeler et al., 2004). This
inverse association is, however, within the range which could be
explained by publication bias, but it does not deny that the wider
range of PON1 activities encountered in populations resulting
from other genetic and acquired influences are relevant to the
development of atherosclerosis. It certainly indicates that the
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substrate specificity involved in the antiatherogenic effect of
PON1 is not greatly influenced by the R192Q polymorphism.
PON1 and PON2 genotype have been linked with
susceptibility to develop diabetes (Rozenberg et al., 2008),
glycaemic control (Hegele et al., 1997), and diabetic
microvascular complications (Mackness et al., 2000; Hofer
et al., 2006; Wang et al., 2013). It has been suggested that this
association reflects a role for oxidation in pancreatic β cell
dysfunction or microvascular disease. Alternatively, it might
reflect an ability of HDL / PON1 to prevent post-translational
protein glycation.
Parenteral administration of partially purified PON1 can
ameliorate experimental atherosclerosis. Recombinant PON1
might also be used for this purpose, if its properties can be
retained during isolation (Draganov et al., 2005; Bajaj et al., 2014).
Intraperitoneal injection of recombinant PON1 inmice increased
cholesterol eﬄux capacity and HDL aryl esterase and lactonase
activities, and decreased macrophage mediated LDL oxidation
(Rosenblat et al., 2011).
Paraoxonase 2 and Paraoxonase 3
PON2 is almost exclusively found intracellularly, whereas PON3
is also associated with HDL, albeit in lesser quantities than PON1.
The primary hydrolytic activity of PON3 is also as a lactonase
(Draganov et al., 2005). PON3 knockout mice are also more
susceptible to atherosclerosis (Zhang et al., 2010), but the reason
for its evolutionary conservation is currently unclear.
Apolipoprotein AI
ApoAI is essential both for the structure of HDL and the
maintenance of the lipid environment in which enzymes such
as PON1 and lecithin: cholesterol acyl transferase (LCAT) can
operate (Rye and Barter, 2014). It is therefore likely to have a
major role in the antioxidant effects of HDL. ApoAI plays a
central role in the redox inactivation of lipid hydroperoxides
which follows their transfer to HDL. ApoAI also creates a
safe environment for the release of lysophospholipids and their
subsequent transfer to the liver. Despite experimental evidence
that lipid-protein complexes containing only apoAI can protect
LDL against oxidation (Karlsson et al., 2015), neither animal
models nor human genetic disorders have provided convincing
evidence that apoAI’s anti-atherogenic effects are independent
of changes in HDL levels (Duverger et al., 1996; Plump et al.,
1997). Interestingly, apoAI-mimetic peptides create circulating
lipid complexes, which associate with other components of HDL
such as PON1 (Mishra et al., 2013). This may provide a means of
enhancing circulating PON1 activity.
Apolipoprotein AII (apoAII)
Apolipoprotein AII (apoAII)-containing HDL particles tend to
be larger and possess less antioxidant activity than those with
higher apoAI content (Karlsson et al., 2015). There is evidence
from both animal models and human studies to suggest that
apoAII might actually suppress PON1 binding to HDL (Litvinov
et al., 2012). Mice expressing human apoAII and apoAI are more
susceptible to atherosclerosis than those expressing apoAI alone.
Other Apolipoproteins
Other apolipoproteins associated with HDL may act
alongside apoAI to inhibit lipid hydroperoxide accumulation.
Apolipoprotein E (apoE) appears to display this anti-oxidative
activity (Miyata and Smith, 1996), while apolipoproteinM
(apoM) has recently been reported to display anti-oxidative
functionality in transgenic mice in addition to facilitating PON1
activity (Elsøe et al., 2012; Borup et al., 2015). There is currently
little evidence that apolipoprotein J (apoJ) contributes to the
anti-oxidative activities of HDL, but it does appear to possess a
variety of functions, including endothelial protection.
Myeloperoxidase (MPO)
Cellular systems contributing to oxidative stress in vivo include
MPO, NADPH oxidase, nitric oxide synthase, and lipoxygenase
(Karlsson et al., 2015). It has recently been proposed that
MPO and PON1 form a ternary complex with HDL, where the
opposing activities of MPO and PON1 determine its oxidation
state and whether HDL is pro- or anti-inflammatory/atherogenic
(Huang et al., 2013). The ratio between these enzyme activities
has also been proposed as a marker of HDL functionality and to
predict coronary risk (Haraguchi et al., 2014).
Glutathione Peroxidase (GSPx)
Although, its levels do not appear to affect coronary heart disease
risk, GSPx is found associated with HDL, where it has the
ability to reduce lipid hydroperoxides (Karlsson et al., 2015).
Similarly, trypanosome lytic factor present in higher density
HDL also exhibits peroxidase activity and may contribute to the
anti-oxidative properties of HDL (Karlsson et al., 2015).
Phospholipase A2
Most PLA2 is associated with LDL, where its activity is an
independent risk factor for coronary heart disease (Rosenson
and Hurt-Camejo, 2012). There is however, no evidence that
the minor fraction of PLA2 activity on HDL is pro-atherogenic.
Furthermore, PLA2 has overlapping activity with PON1 and it
remains unclear just how much of the hydrolysis of platelet
activating factor by HDL is due to PLA2 and how much to
PON1 (Rodrigo et al., 2001). PLA2 on HDL is likely to contribute
anti-oxidative activity by the same mechanism as PON1, by
hydrolyzing lipid hydroperoxides. This activity, which would
be pro-atherogenic on LDL in the presence of apoB, may be
antiatherogenic in the environment provided by HDL.
Lecithin: Cholesterol Acyl Transferase
Similarly, there is currently limited evidence to support a role
for LCAT in the antioxidative activity of HDL (Holleboom et al.,
2012), but its association with HDL and, like PON1 and PLA2,
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its role in generating lysophospholipids, does contribute to the
hypothesis that HDL provides a safe place to release lysolipids
otherwise potentially damaging to cell membranes and other
lipoproteins.
Cholesteryl Ester Transfer Protein (CETP)
and Phospholipid Transfer Protein (PLTP)
The antioxidant activity of HDL occurs following the transfer
of lipid hydroperoxides to HDL. Experimentally no additional
facilitator of transfer to HDL is required, but some CETP and
PLTP are likely to remain in physical association with HDL
after its isolation. CETP can accelerate the transfer of both
cholesteryl ester and phospholipid hydroperoxides (Christison
et al., 1995). CETP and/or PLTP may thus be important for
the anti-oxidative effect of HDL in vivo. Like PON1, PLTP is
found predominantly in small, dense HDL, where it is able
to interact with apolipoproteins implicated in anti-oxidative
function, including apoAI, apoAII, and apoJ (Karlsson et al.,
2015).
Conclusion
The capacity of HDL to protect LDL against oxidative
modification is considerable, but its potential therapeutic use
to prevent atherosclerosis is as yet unfulfilled. The interaction
of lipids with apoAI in HDL provides a lipoprotein particle
capable of acquiring potentially toxic lipids and holding them
in an environment where they may be safely hydrolyzed and
from which they may be released to the liver for elimination.
PON1, PLA2, and LCAT are present at higher concentrations
in small, dense, protein-rich HDL (Karlsson et al., 2015), and
HDL particles are therefore heterogeneous in their anti-oxidative
capacity. PON1 is likely to be critical to the antioxidative
capacity of HDL, but is likely to require a lipid environment
to support its activity. Separation of HDL from PON1 disrupts
this and the necessary environment is only imperfectly present
with the currently available water-soluble recombinant forms
of PON1. Acting together on HDL, PON1, apoAI, apoM,
and PLA2 in conjunction with CETP and other lipid transfer
proteins probably create a system with both antioxidative and
antiglycative properties (see Figure 1).
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